Health

Opioid Prescriptions Dropped In Every State Last Year

Written by admin

<div _ngcontent-c20 innerhtml="

IQVIA Institute

Opioid prescriptions have dropped to 2006 levels.

The number of prescriptions of opioid painkillers dropped 10.2% in 2017, according to the IQVIA Institute, an arm of the clinical research giant that collects data on pharmaceutical prescriptions from retail pharmacies.

Prescriptions of high-potency opiates dropped even more – 16.1%. And when a measure called morphine milligram equivalents, which measures both the number of prescriptions and the strength of the drugs provided, the resulting 12% drop is the largest in 25 years, IQVIA says.

“We’re seeing declines across every state,” says Murray Aitken, executive director of the IQVIA Institute. “The states that have the highest per capita consumption are also the states with the highest decline.” But Aitken also offers a cautionary note: though opioid prescriptions have been dropping since 2011, they are still about six times higher than they were in 1992.

Some other takeaways from he annual report on medicine use in the US from IQVIA, which was formerly known as IMS Health before its merger with Quintiles:

  • Drug prices are growing more slowly. The growth in net prices, the amount pocketed by drug companies, was just 0.6% in 2017. Generic drug prices, which seemed to be increasing over the past few years, are down, too.
  • Patients’ out-of-pocket costs at the pharmacy are down, on average, but a few are paying a lot more. The average price for a branded drug increased 58% from $231 to $364 over the past five years, but the average out-of-pocket cost was flat at $30. Almost 31% of prescriptions cost the patient nothing. One reason: drug companies are using coupons and other mechanisms to cover the co-payments to insurance companies for their drugs.
    But 2.5% of prescriptions cost more than $50. The patients paying for those prescriptions paid 41% of all pharmacy out-of-pocket costs. Interestingly, greater exposure to drug costs has not led people to abandon their medicines at significantly greater rates.
  • A few more interesting stats: Prescriptions for mental health treatments have tripled since 1992, mostly due to the wider use of antidepressants. There are 2,601 experimental drugs in the late stages of testing, of which 748 (29%) are for cancer. IMS expects 40 to 45 new drugs to be approved a year for the next five years. But it also is cutting its forecast for growth in net prices for branded drugs to 1% from 4%. One of the biggest uncertainties: whether there is significant uptake of biosimilars, or generic versions of expensive biotech drugs.

To stay in the loop with Forbes Health coverage, subscribe to the Innovation Rx newsletter here.

“>

IQVIA Institute

Opioid prescriptions have dropped to 2006 levels.

The number of prescriptions of opioid painkillers dropped 10.2% in 2017, according to the IQVIA Institute, an arm of the clinical research giant that collects data on pharmaceutical prescriptions from retail pharmacies.

Prescriptions of high-potency opiates dropped even more – 16.1%. And when a measure called morphine milligram equivalents, which measures both the number of prescriptions and the strength of the drugs provided, the resulting 12% drop is the largest in 25 years, IQVIA says.

“We’re seeing declines across every state,” says Murray Aitken, executive director of the IQVIA Institute. “The states that have the highest per capita consumption are also the states with the highest decline.” But Aitken also offers a cautionary note: though opioid prescriptions have been dropping since 2011, they are still about six times higher than they were in 1992.

Some other takeaways from he annual report on medicine use in the US from IQVIA, which was formerly known as IMS Health before its merger with Quintiles:

  • Drug prices are growing more slowly. The growth in net prices, the amount pocketed by drug companies, was just 0.6% in 2017. Generic drug prices, which seemed to be increasing over the past few years, are down, too.
  • Patients’ out-of-pocket costs at the pharmacy are down, on average, but a few are paying a lot more. The average price for a branded drug increased 58% from $231 to $364 over the past five years, but the average out-of-pocket cost was flat at $30. Almost 31% of prescriptions cost the patient nothing. One reason: drug companies are using coupons and other mechanisms to cover the co-payments to insurance companies for their drugs.
    But 2.5% of prescriptions cost more than $50. The patients paying for those prescriptions paid 41% of all pharmacy out-of-pocket costs. Interestingly, greater exposure to drug costs has not led people to abandon their medicines at significantly greater rates.
  • A few more interesting stats: Prescriptions for mental health treatments have tripled since 1992, mostly due to the wider use of antidepressants. There are 2,601 experimental drugs in the late stages of testing, of which 748 (29%) are for cancer. IMS expects 40 to 45 new drugs to be approved a year for the next five years. But it also is cutting its forecast for growth in net prices for branded drugs to 1% from 4%. One of the biggest uncertainties: whether there is significant uptake of biosimilars, or generic versions of expensive biotech drugs.

To stay in the loop with Forbes Health coverage, subscribe to the Innovation Rx newsletter here.

Let’s block ads! (Why?)


Source link

About the author

admin

Leave a Comment